ACTU

Actuate Therapeutics, Inc. (ACTU) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer through the inhibition of glycogen synthase kinase-3 (GSK-3). The company's sole product candidate is elraglusib, currently in Phase 2 trials for metastatic pancreatic ductal adenocarcinoma (mPDAC) and Phase 1/2 trials for refractory pediatric malignancies. The company has no approved products and has not generated any revenue since inception.

Key Financial Metrics

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by approximately $1.98 million compared to Q1 2024, primarily due to a significant reduction in Research and Development (R&D) expenses.
• R&D Expenses: Decreased by $3.64 million to $3.22 million. This was driven by a $3.26 million drop in external clinical trial expenses (fewer patients on study in the randomized Phase 2 mPDAC trial) and reduced preclinical and CMC costs.
• G&A Expenses: Increased by $2.23 million to $3.15 million. This increase was largely due to higher personnel-related expenses (including a $920,917 increase in stock-based compensation) and increased costs associated with operating as a public company (insurance, board fees, legal).
• Other Income/Expense: Improved from a net expense of $(522,805) in Q1 2024 to net income of $48,560 in Q1 2025. The prior year included non-cash losses related to the fair value of warrant liabilities and convertible notes, which were resolved or reclassified following the August 2024 IPO.
• Liquidity: Cash balances decreased by $4.75 million during the quarter due to operating burn, despite a higher starting cash balance compared to the prior year.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for one year from the filing date. Cash on hand is estimated to be insufficient to meet operational requirements beyond the second quarter of fiscal year 2025.
• Capital Requirements: The company requires substantial additional capital in the near term to fund operations and clinical development. Failure to secure funding could force delays, reductions, or termination of development programs.
• Committed Equity Facility: On March 27, 2025, the company entered into an agreement with B. Riley Principal Capital II allowing the sale of up to $50 million of common stock over 36 months. As of the filing date, no shares had been sold under this facility, though subsequent events noted sales of 72,082 shares for approximately $597,000 in net proceeds between April and May 2025.
• Key Risks:
  • Dependence on the success of elraglusib as the sole product candidate.
  • Reliance on a single manufacturer in China for drug substance, exposing the company to geopolitical and tariff risks.
  • Potential dilution from future equity financings.
  • Uncertainty regarding clinical trial outcomes and regulatory approval.

Investor Verification Checklist

• Cash Runway: Verify the company's ability to raise capital before the end of Q2 2025 to avoid operational disruption.
• Committed Equity Facility Utilization: Monitor the frequency and pricing of share sales under the B. Riley facility to assess dilution impact and capital raised.
• Clinical Trial Progress: Review updates on the Actuate-1801 (mPDAC) and Actuate-1902 (pediatric) trials, as these are the primary drivers of future value.
• Supply Chain Risks: Assess any developments regarding the Chinese manufacturer of elraglusib drug substance and potential tariff impacts.
• Stock-Based Compensation: Note the significant increase in G&A due to stock-based compensation; monitor future grant activity and its impact on cash burn.